Replies to post #600279 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Didn't read beyond 'NOT a scientific presentation.' That was enough.

[CrashOverride]

You don't get to dictate our excitement.

[dstock07734]

OJ,

Not a scientific presentation? Are you kidding me? If this is not a scientific presentation, what will be? Lecture us with an example of a scientific presentation. It is a top-notch scientific presentation. BTW, have you done any research and presented your research?

I have been wondering what Dr. Subbiah has been doing since NWBO has provided research for him for many years. I think I can see the trace of Dr. Subbiah's research.

Here are different types of peptides that are tumor related. Choose any one of them and go through Dr. Subbiah publications to see if these peptides show up in some of his publications.

[meirluc]

Calmed down meirluc to calm OncoJock: How likely is it that DCVax-L which greatly invigorates our agnostic immunological mechanism's ability to destroy glioblastomas, will not basically function identically (agnostically) to destroy solid tumors located in other parts of our body?

I believe that it is extremely likely and explains the optimism of many of us on this MB.

[Roman516]

Not so fast OJ
Per your comment
"The presentation by Marnix Bosch at ASCO was NOT a scientific presentation, despite the venue."
This is your opinion.

As for many others, that is not what I heard from the people who were actually at the presentation.

[VuBru]

Onco - I agree it was not a peer-reviewed scientific presentation at ASCO, but that does not take away from the science presented. I have no idea whether these claims of tissue agnostic approvals will happen or how likely they are. However, what excites me the most about the ASCO presentation is that clearly the company and scientific advisors have been working on defining and documenting the MOA of DCVAX. Having an identified MOA will help offset the likely criticisms of the phase 3 trial design (use of external controls) during the approval process for GBM with regulatory authorities. In the absence of a MOA, it would be much easier for FDA advisors to simply claim the positive phase 3 results were the result of selection bias and differences between the DCVAX sample and prior phase 3 trials used as external controls. Now that argument is much less convincing since we can see why DCVAX should have been effective in the trial.

[Maverick0408]

I agree with you. Dead money in 2023. Although the supporters are trying their best to pump!

The management themselves have said we plan to be strategic and be prepared to file by the end of this year. And going by their excellent execution history, it’s likely the applications get pushed out to first half of next year because they have repeatedly shown that they are unable to meet even their own most conservative timelines.

Also, notice that Advent folks are going out to quite a few cell and gene therapy conferences to promote their services. They are looking for new clients! So something to keep in mind and not correlate their expansion to NWBO alone.

[muee88]

Was information about science presented? Yes. As such, it was a scientific presentation. Considering you are a “jock,” maybe you just don’t know what science is.

[vator]

It was scientific. If it had a bit of sales promotion by understanding the MOA, who cares? I feel more comfortable and as someone has stated earlier who appears to be medically knowledgeable, it will not be long before clinicians will start to use DCVax along with Poly ICLC.

Let’s face the fact it is exhibiting a ten times better response than current SOC for GBM. What oncologist is going to deny that to their patient? I am sure the MHRA is aware of this by now. According to Liau clinicians now are searching and using anything off-label in GBM that gives their patients a better chance. MHRA approval will start the stone rolling downhill. And it will be rapid.

[skitahoe]

OJ,

I'll agree with you that Dr. Bosch's presentation wasn't peer reviewed, but I do believe he showed some scientific information that hadn't ever been shown before, and it was important. I believe he said more about T-cells than any presentation I can remember in the past and the graphics involved were excellent.

I really don't believe anyone outside of the company and regulators they've been speaking with know how close we are to filing for approvals. They could come Monday, or not for months, we just don't know. They could file with just the UK, or all four regulators together, only they know what they intend to do.

I'm like many others here, willing to speculate as to what they may do, but it's just that, speculation. When they do something, or perhaps say something, we'll know more than we do today. Until then we're all free to be as positive, or negative as we wish to be.

I believe the gradual share price growth recently is an indication that new investors are learning of NWBO and getting in. The higher our price goes before news the better IMHO. Without further news I'd not be surprised if we see $1 or more by the end of June, with any positive news it could go much higher than that. Some may say it's dead money for this year, but a close this year above $1 is roughly double my investment, and I think that's true for many others, very few of my friends wouldn't be thrilled by their investments being worth twice what they paid in a matter of a few years.

Gary